Ipraxa Steri-Neb

Ipratropium bromide, the active ingredient in Ipraxa Steri-Neb, is an anticholinergic (muscarinic antagonist) presented as a nebulized solution for inhalation use. It is employed to relieve bronchoconstriction and reduce mucus secretion in patients with chronic obstructive pulmonary disease, asthma and other bronchospastic conditions.

GNH USA supplies Ipraxa Steri-Neb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution in multiple regions.

Ipratropium bromide is used as a bronchodilator to manage airway obstruction in several respiratory conditions. - Chronic obstructive pulmonary disease (COPD): improves airflow and reduces exacerbations. - Asthma (adjunct therapy): enhances bronchodilation when combined with other agents. - Bronchospasm: provides rapid relief of acute bronchoconstriction.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and related to the inhalation route.

Common Side Effects: - Dry mouth: sensation of reduced salivation. - Cough: irritation of the airway during inhalation. - Throat irritation: mild soreness or discomfort. - Nasal congestion: blockage or stuffiness. - Headache: mild to moderate pain.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening airway narrowing. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Urinary retention: difficulty urinating, especially in predisposed patients. - Glaucoma exacerbation: increased intra‑ocular pressure.

Before prescribing Ipraxa Steri‑Neb, consider the following precautions to ensure safe and effective use. - Assess respiratory status: confirm diagnosis of COPD, asthma or bronchospasm. - Review anticholinergic sensitivity: avoid in patients with known hypersensitivity to ipratropium or similar agents. - Monitor for urinary retention: especially in elderly males with prostate enlargement. - Caution in glaucoma: use with care in patients with narrow‑angle glaucoma. - Avoid concurrent use with long‑acting anticholinergics without medical supervision. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Ipratropium bromide can interact with other medications; awareness of these interactions helps prevent reduced efficacy or increased adverse effects.

Major Interactions (Avoid): - Concurrent long‑acting anticholinergics: may increase anticholinergic burden. - Beta‑agonists in high doses: risk of additive cardiovascular effects.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance anticholinergic side effects such as dry mouth. - MAO inhibitors: potential for exaggerated bronchodilator response. - Ophthalmic anticholinergics: increased risk of intra‑ocular pressure elevation.